Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2018

View Archived Issues

OHM Oncology acquires rights to Aptose's APL-581 and related molecules

MaaT Pharma receives authorization to launch European phase II study in severe GvHD

JW Therapeutics completes series A financing

Corvus commences public offering of common stock

TGV Therapeutics and NIH to collaborate on development of novel antifungal agent

Bioverativ now fully owned subsidiary of Sanofi

Aeglea Biotherapeutics provides update on clinical trials of pegzilarginase

Loss of USP28 shown to confer poorer overall survival to melanoma patients

Pivotal phase III GLOBE study of VB-111 does not meet primary endpoint

Prokaryotics awarded NIAID grant to support antibiotic program

FDA accepts NDA for TX-001-HR

Caladrius Biosciences announces interim results from phase II trial of CLBS-03 in type 1 diabetes

CPI-1205 well tolerated in B-cell lymphoma trial

MyoKardia reports Cohort B data from phase II PIONEER-HCM study of mavacamten

Arsanis Biosciences, Max-Planck-Gesellschaft patent antibodies targeting K. pneumoniae

Menarini submits MAA in Europe for delafloxacin

Medical Prognosis Institute and Oncology Venture Sweden propose merger

Novel compounds for treating HIV infection identified at Gilead

Pfizer reports positive outcome of FDA committee meeting on tofacitinib for ulcerative colitis

Henry Ford Health System presents therapeutic mammalian exosomes

Senhwa Biosciences presents phase I data for CX-5461 in patients with solid tumors

Cigna to acquire Express Scripts

Anti-EGFR AVID-100 well tolerated in phase I trial